The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Impact of bridging therapy on the outcomes of patients with R/R myeloma treated with ide-cel
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on the results of a retrospective study evaluating the impact of bridging therapy on the outcomes of patients with relapsed/refractory (R/R) multiple myeloma treated with idecabtagene vicleucel (ide-cel). The results suggested that patients who did not need bridging therapy had better outcomes in comparison to patients who received bridging therapy. In addition, certain types of bridging therapy appeared to be associated with improved outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
